Siegel RL, Miller KD and Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017, 67: 7-30.
 Reed N, Millan D, Verheijen R and Castiglione M. Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. ANN ONCOL 2010, 21 Suppl 5: v31-v36.
 Ozols RF, Bookman MA, Connolly DC, Daly MB, Godwin AK, Schilder RJ, Xu X and Hamilton TC. Focus on epithelial ovarian cancer. CANCER CELL 2004, 5: 19-24.
 Narod S. Can advanced-stage ovarian cancer be cured? NAT REV CLIN ONCOL 2016, 13: 255-261.
 van Haaften-Day C, Shen Y, Xu F, Yu Y, Berchuck A, Havrilesky LJ, de Bruijn HW, van der Zee AG, Bast RJ and Hacker NF. OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal. CANCER-AM CANCER SOC 2001, 92: 2837-2844.
 Dayyani F, Uhlig S, Colson B, Simon K, Rolny V, Morgenstern D and Schlumbrecht M. Diagnostic Performance of Risk of Ovarian Malignancy Algorithm Against CA125 and HE4 in Connection With Ovarian Cancer: A Meta-analysis. INT J GYNECOL CANCER 2016, 26: 1586-1593.
 Chan KK, Chen CA, Nam JH, Ochiai K, Wilailak S, Choon AT, Sabaratnam S, Hebbar S, Sickan J, Schodin BA and Sumpaico WW. The use of HE4 in the prediction of ovarian cancer in Asian women with a pelvic mass. GYNECOL ONCOL 2013, 128: 239-244.
 Van Gorp T, Cadron I, Despierre E, Daemen A, Leunen K, Amant F, Timmerman D, De Moor B and Vergote I. HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. Br J Cancer 2011, 104: 863-870.
 Moshkovskii SA, Vlasova MA, Pyatnitskiy MA, Tikhonova OV, Safarova MR, Makarov OV and Archakov AI. Acute phase serum amyloid A in ovarian cancer as an important component of proteome diagnostic profiling. Proteomics Clin Appl 2007, 1: 107-117.
 Tamamoto T, Ohno K, Ohmi A, Goto-Koshino Y and Tsujimoto H. Verification of measurement of the feline serum amyloid A (SAA) concentration by human SAA turbidimetric immunoassay and its clinical application. J VET MED SCI 2008, 70: 1247-1252.
 Kushner I. The acute phase response: an overview. Methods Enzymol 1988, 163: 373-383.
 Malle E and De Beer FC. Human serum amyloid A (SAA) protein: a prominent acute-phase reactant for clinical practice. EUR J CLIN INVEST 1996, 26: 427-435.
 Armstrong H, Bording-Jorgensen M, Dijk S and Wine E. The Complex Interplay between Chronic Inflammation, the Microbiome, and Cancer: Understanding Disease Progression and What We Can Do to Prevent It. Cancers (Basel) 2018, 10.
 Malle E, Sodin-Semrl S and Kovacevic A. Serum amyloid A: an acute-phase protein involved in tumour pathogenesis. CELL MOL LIFE SCI 2009, 66: 9-26.
 Biaoxue R, Hua L, Wenlong G and Shuanying Y. Increased serum amyloid A as potential diagnostic marker for lung cancer: a meta-analysis based on nine studies. BMC CANCER 2016, 16: 836.
 Yang M, Liu F, Higuchi K, Sawashita J, Fu X, Zhang L, Zhang L, Fu L, Tong Z and Higuchi K. Serum amyloid A expression in the breast cancer tissue is associated with poor prognosis. ONCOTARGET 2016, 7: 35843-35852.
 Ren Y, Wang H, Lu D, Xie X, Chen X, Peng J, Hu Q, Shi G and Liu S. Expression of serum amyloid A in uterine cervical cancer. DIAGN PATHOL 2014, 9: 16.
 Wood SL, Rogers M, Cairns DA, Paul A, Thompson D, Vasudev NS, Selby PJ and Banks RE. Association of serum amyloid A protein and peptide fragments with prognosis in renal cancer. Br J Cancer 2010, 103: 101-111.
 Chan DC, Chen CJ, Chu HC, Chang WK, Yu JC, Chen YJ, Wen LL, Huang SC, Ku CH, Liu YC and Chen JH. Evaluation of serum amyloid A as a biomarker for gastric cancer. ANN SURG ONCOL 2007, 14: 84-93.
 Cocco E, Bellone S, El-Sahwi K, Cargnelutti M, Buza N, Tavassoli FA, Schwartz PE, Rutherford TJ, Pecorelli S and Santin AD. Serum amyloid A: a novel biomarker for endometrial cancer. CANCER-AM CANCER SOC 2010, 116: 843-851.
 REN Yanjie,WANG He,LU Donghao,et al.Expression of serum amyloid A inuterine cervical cancer.Diagnostic Pathology,2014,9(1):16.
 Lu SY, Rodriguez M and Liao WS. YY1 represses rat serum amyloid A1 gene transcription and is antagonized by NF-kappa B during acute-phase response. MOL CELL BIOL 1994, 14: 6253-6263.
 Ren Y and Liao WS. Transcription factor AP-2 functions as a repressor that contributes to the liver-specific expression of serum amyloid A1 gene. J BIOL CHEM 2001, 276: 17770-17778.
 Nguyen KD, Macaubas C, Truong P, Wang N, Hou T, Yoon T and Mellins ED. Serum amyloid A induces mitogenic signals in regulatory T cells via monocyte activation. MOL IMMUNOL 2014, 59: 172-179.
 Wang JY,Zheng YZ,Yang J,Lin YH,Dai SQ,Zhang G,Liu WL.Elevated levels of serum amyloid A indicate poor prognosis in patients with esophageal squamous cell carcinoma.BMC Cancer.2012;doi:10.1186/1471-2407-12.365.
 O'Hara R, Murphy EP, Whitehead AS, FitzGerald O and Bresnihan B. Local expression of the serum amyloid A and formyl peptide receptor-like 1 genes in synovial tissue is associated with matrix metalloproteinase production in patients with inflammatory arthritis. Arthritis Rheum 2004, 50: 1788-1799.
 Tamamoto T, Ohno K, Goto-Koshino Y and Tsujimoto H. Effects of serum amyloid A on matrix metalloproteinase-9 production in feline lymphoma-derived cell lines. Vet Immunol Immunopathol 2017, 187: 10-13.
 Deng G, Zhou F, Wu Z, Zhang F, Niu K, Kang Y, Liu X, Wang Q, Wang Y and Wang Q. Inhibition of cancer cell migration with CuS@ mSiO2-PEG nanoparticles by repressing MMP-2/MMP-9 expression. Int J Nanomedicine 2018, 13: 103-116.
 An J, Xue Y, Long M, Zhang G, Zhang J and Su H. Targeting CCR2 with its antagonist suppresses viability, motility and invasion by downregulating MMP-9 expression in non-small cell lung cancer cells. ONCOTARGET 2017, 8: 39230-39240.
 Zhao Y, Zhou S and Heng CK. Celecoxib inhibits serum amyloid a-induced matrix metalloproteinase-10 expression in human endothelial cells. J VASC RES 2009, 46: 64-72.
 Lee HY, Kim MK, Park KS, Bae YH, Yun J, Park JI, Kwak JY and Bae YS. Serum amyloid A stimulates matrix-metalloproteinase-9 upregulation via formyl peptide receptor like-1-mediated signaling in human monocytic cells. Biochem Biophys Res Commun 2005, 330: 989-998.
 De Buck M, Gouwy M, Wang JM, Van Snick J, Opdenakker G, Struyf S and Van Damme J. Structure and Expression of Different Serum Amyloid A (SAA) Variants and their Concentration-Dependent Functions During Host Insults. CURR MED CHEM 2016, 23: 1725-1755.
 Urieli-Shoval S, Finci-Yeheskel Z, Dishon S, Galinsky D, Linke RP, Ariel I, Levin M, Ben-Shachar I and Prus D. Expression of serum amyloid a in human ovarian epithelial tumors: implication for a role in ovarian tumorigenesis. J HISTOCHEM CYTOCHEM 2010, 58: 1015-1023.
 Hanahan D and Weinberg RA. Hallmarks of Cancer: The Next Generation. CELL 2011, 144: 646-674.
 Tamamoto T, Ohno K, Goto-Koshino Y and Tsujimoto H. Serum amyloid A promotes invasion of feline mammary carcinoma cells. J VET MED SCI 2014, 76: 1183-1188.
 Shay G, Lynch CC and Fingleton B. Moving targets: Emerging roles for MMPs in cancer progression and metastasis. MATRIX BIOL 2015, 44-46: 200-206.
 Lee HY, Kim M, Park KS, Bae YH, Yun J, Park J, Kwak J and Bae Y. Serum amyloid A stimulates matrix-metalloproteinase-9 upregulation via formyl peptide receptor like-1-mediated signaling in human monocytic cells. BIOCHEM BIOPH RES CO 2005, 330: 989-998.
 Arvelo F, Sojo F and Cotte C. Tumour progression and metastasis. Ecancermedicalscience 2016, 10: 617.
 Ha GH, Park JS and Breuer EK. TACC3 promotes epithelial-mesenchymal transition (EMT) through the activation of PI3K/Akt and ERK signaling pathways. CANCER LETT 2013, 332: 63-73.
 Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES and Mesirov JP. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102:15545-15550.
 Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstrale M, Laurila E, Houstis N, Daly MJ, Patterson N, Mesirov JP, Golub TR, Tamayo P, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003; 34:267-273.
. Tazzari PL, Cappellini A, Grafone T, Mantovani I, Ricci F, Billi AM, Ottaviani E, Conte R, Martinelli G and Martelli AM. Detection of serine 473 phosphorylated Akt in acute myeloid leukaemia blasts by flow cytometry. Br J Haematol. 2004; 126:675-681.
. Kuo YC, Huang KY, Yang CH, Yang YS, Lee WY and Chiang CW. Regulation of phosphorylation of Thr-308 of Akt, cell proliferation, and survival by the B55alpha regulatory subunit targeting of the protein phosphatase 2A holoenzyme to Akt. J Biol Chem. 2008; 283:1882-1892.
 Coloff JL, Mason EF, Altman BJ, Gerriets VA, Liu T, Nichols AN, Zhao Y, Wofford JA, Jacobs SR, Ilkayeva O, Garrison SP, Zambetti GP and Rathmell JC. Akt requires glucose metabolism to suppress puma expression and prevent apoptosis of leukemic T cells. J Biol Chem. 2011; 286:5921-5933.
 Jae W. Lee, Meredith L. Stone, Paige M. Porrett, Stacy K. Thomas, et al. Hepatocytes direct the formation of a pro-metastatic niche in the liver. Nature,2019,567(7747):249-252.